1 Saultz JN,Garzon R.Acute myeloid leukemia:a concise review[J].J Clin Med,2016,5(3):33. 2 Tobin LA,Robert C,Rapoport AP,et al.Targeting abnormal DNA double-strand breakrepair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias[J].Oncogene,2013,32(14):1784-1793. 3 Faraoni I,Aloisio F,De Gabrieli A,et al.The poly(ADP-ribose)polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation[J].Cancer Lett,2018,423:127-138. 4 Stou D,Akbani B.Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J].N Engl J Med,2013,368(22):2059-2074. 5 Esposito MT,Zhao L,Fung TK,et al.Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors[J].Nat Med,2015,21(12):1481-1490. 6 Faraoni I,Compagnone M,Lavorgna S,et al.BRCA1,PARP1 and γH2AX in acute myeloid leukemia:Role as biomarkers of response to the PARP inhibitor olaparib[J].Biochim Biophys Acta,2015,1852(3):462-472. 7 Meng XW,Koh BD,Zhang JS,et al.Poly(ADP-ribose)polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression[J].J Biol Chem,2014,289(30):20543-20558. 8 Dulaney C,Marcrom S,Stanley J,et al.Poly(ADP-ribose)polymerase activity and inhibition in cancer[J].Semin Cell Dev Biol,2017,63:144-153. 9 黄胜辉,黄志勇.PARP-1:一个肿瘤治疗的新靶点[J].世界华人消化杂志,2006,14(9):841-847. 10 Koh DW,Dawson TM,Dawson VL.Mediation of cell death by poly(ADP-ribose)polymerase-1[J].Pharmacol Res,2005,52(1):5-14. 11 Mariano G,Ricciardi MR,Trisciuoglio D,et al.PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment,targeting Snail expression[J].Oncotarget,2015,6(17):15008-15021. 12 Muvarak NE,Chowdhury K,Xia L,et al.Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents-a potential therapy for cancer[J].Cancer Cell,2016,30(4):637-650. 13 Wu J,Xiao S,Yuan M,et al.PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis[J].Mol Med Rep,2019,19(1):75-84. |